Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine in Moderate and Severe COVID-19
NCT05151614Phase 1Completed
- Sponsor
- University of Baghdad
- Start
- Apr 2021
- Primary completion
- Oct 2021
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of colchicine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by University of Baghdad. Primary endpoints: Percentage of cure of the patients at 14 days and Time to recovery at 14 days. Started Apr 2021; status: completed.
02
Drugs
colchicine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05151614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05151614.